Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREMIUM trial of prasugrel monotherapy after primary PCI for STEMI
jRCTs052220145Active, not recruiting
- Sponsor
- Boston Scientific Corporation
- Start
- Apr 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of prasugrel and aspirin in myocardial infarction (MI) (2 arms), sponsored by Boston Scientific Corporation. Primary endpoint: Primary cardiovascular composite endpoint. Started Apr 2023; status: active, not recruiting.
02
Drugs
prasugrelaspirin
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on jRCTs052220145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs052220145.